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Abstract
Bloodstream and other invasive infections due to Candida species (invasive fungal diseases = IFD) are a major cause of morbidity and
mortality in hospitalized adults and children in many countries worldwide. The high infection-related morbidity and mortality associated
with invasive Candida infection/candidaemia (IC/C), combined with suboptimal diagnostic tools, have driven the overuse of antifungal drugs.
Antifungal stewardship (AFS) may be regarded as subentity of the more general term Anti-infective or Antimicrobial Stewardship Program
(AIS/AMS). The high costs and high contribution of antifungal agents to the management of IFDs along with their recognized toxicities have
been addressed as the principal justiﬁcation for antifungal stewardship. AFS programmes should be organized by an interdisciplinary team of
clinicians, pharmacists, microbiologists and infection control experts with the lead of an infectious disease specialist preferably in each large
hospital/institution dealing with high-risk patients for invasive fungal infections. These programmes should consider various aspects of IC/C
including (i) the local fungal epidemiology, (ii) information on antifungal resistance rates, (iii) establishing and application of therapeutic
guidelines, (iv) implementation of treatment strategies for empirical, pre-emptive therapy including PK/PD data for antifungal drugs, de-
escalation and ‘switch and step-down strategies’ (from intravenous to oral medication) in deﬁned patient populations, (v) catheter
management together with the application of routine diagnostic procedures such as ophthalmological and cardiac evaluations and (vi) the
best available diagnostic tests for diagnosing IC and candidaemia.
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Introduction
Infection-related mortality due to IC/C remains high, in
particular in severely ill patients in the ICU and when antifungal
therapy is delayed. The high infection-related morbidity and
mortality associated with IC, combined with suboptimal
diagnostic tools, have driven the overuse of antifungal drugs
in therapy and prophylaxis of IC/C. The concept of
anti-infective stewardship may be deﬁned as an ongoing effort
by a healthcare institution to optimize antimicrobial use in
order to improve patient outcomes, ensure cost-effective
therapy and reduce adverse sequelae [1–4]. This includes the
appropriate use of antimicrobials by selecting the proper drug,
dosage, duration and route of administration. Antimicrobial
resistance—a consequence of the use and misuse of antimi-
crobial medicines—occurs when a micro-organism becomes
resistant to an antimicrobial drug to which it was previously
sensitive. Primary and acquired (or secondary) resistance to
antifungal drugs is known for several pathogenic fungi (e.g.
yeasts such as Candida spp., and moulds such as Aspergillus spp.
or Mucorales) [5,6]. Resistance mechanisms have been exten-
sively described, in particular for Candida albicans against
ﬂuconazole with potential cross-resistance to other azole
antifungals [6]. Current issues related to treatment for invasive
Candida infections include aspects such as choice of the optimal
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antifungal drug for candidaemia, balance between overuse
(empirical therapy) and underuse (waiting until proven disease)
of antifungal therapy in severely ill patients, step-down
strategies, implementation of PK/PD in everyday practice,
emergence of non-Candida albicans infections, the role of
noncultural diagnostic tests and pharmacoeconomics (see
Table 1).
Antifungal Stewardship for IC/C
According to the Policy Statement on Antimicrobial Stew-
ardship by the Society for Healthcare Epidemiology of
America (SHEA), the Infectious Diseases Society of America
(IDSA) and the Pediatric Infectious Diseases Society (PIDS),
antimicrobial stewardship (AMS) is deﬁned as a programme
with coordinated interventions designed to improve and
measure the appropriate use of antimicrobial agents by
promoting the selection of the optimal antimicrobial drug
regimen including dosing, duration of therapy and route of
administration [7] (see Table 2). Antifungal stewardship (AFS)
refers to a programme or series of interventions to monitor
and direct antifungal use at a healthcare institution. According
to Tamma and Cosgrove, the most effective antimicrobial
stewardship programmes simultaneously incorporate multiple
strategies after collaborating with the various specialties
within a given healthcare facility, although interventions on a
smaller scale to improve antimicrobial use are also valuable in
some settings [8]. An understanding of the pharmacokinetics
and pharmacodynamics (PK/PD) of these drugs has been
demonstrated as important to optimize drug choice and
dosing regimen [9]. Optimizing the use of currently available
antifungal agents is not only inﬂuenced by antifungal drug
properties (spectrum of activity, PK/PD, mode of action,
route of application) but by their high cost and drug-related
toxicities as well. However, reduction in healthcare costs
should be regarded only as a secondary goal of AFS.
Challenges for the Implementation of AFS in
Candida Infections
Implementation of an AFS programme using a comprehensive
care bundle for the treatment for candidaemia has been shown
to improve management of infected patients [10]. Key issues of
the strategy in a study from Michigan/USA were as follows: (i)
utilization appropriate antifungal drugs with appropriate dura-
tion of use, (ii) removal of intravenous catheters, (iii) adequate
diagnostics with repeated blood cultures and (iv) performance
of ophthalmologic examinations [10]. In a prospective study on
AFS in IC/C from Thailand, interventions included education,
introduction of an antifungal hepatic and/or renal dose
adjustment tool, antifungal prescription forms and prescrip-
tion-control strategies [11]. Accordingly, for the implementa-
tion of an effective AFS programme, various important aspects
and questions need to be considered.
What is the adequate diagnosis of IC/C and the role of
noncultural tests (e.g. Ag/Ab, ß-D-Glucan, PCR)?
Blood cultures (BC) are still the method of choice for the
diagnosis of candidaemia. Two pairs of blood culture bottles
(10 mL each) should be obtained for aerobic and anaerobic
culture when candidaemia is suspected before the initiation of
antifungal therapy [12]. Standard BC media detect most
Candida species. It appears that the detection of C. glabrata is
TABLE 1. Current issues related to treatment for invasive
Candida infections
Which is the optimal antifungal drug treatment for candidaemia?
How to balance between overuse (empirical therapy) and underuse (waiting until
proven disease) of antifungal therapy in severely ill patients
How long do handle central lines and do we need to treat in patients with
catheter-related candidaemia vs. other forms of invasive Candida infections?
What is the importance of Candida nonalbicans infections for the choice of initial
therapy?
What is the appropriate choice of drugs in patient groups/hospitals with high
prevalence of azole resistance?
What is the role of noncultural tests (e.g. Ag/Ab, ß-D-Glucan, PCR)?
Should different patient populations be treated differently (e.g. granulocytopenic)?
How to treat patients with invasive Candida infection and organ failure (e.g. renal
and/or liver), severe sepsis or septic shock?
When to apply step-down strategies (switch from i.v. to oral)?
When and how to implement PK/PD in everyday antifungal treatment?
Which antifungal therapy is most cost-effective (pharmacoeconomics)?
TABLE 2. Minimum requirements for developing an institu-
tional programme to enhance Antifungal Stewardship
(adapted from Policy Statement on Antimicrobial Steward-
ship by the Society for Healthcare Epidemiology of America
(SHEA), the Infectious Diseases Society of America (IDSA)
and the Pediatric Infectious Diseases Society (PIDS))
Creation of a multidisciplinary interprofessional antifungal stewardship team
that is physician directed or supervised. Team members should include but
are not limited to:
 a physician
 a pharmacist
 a clinical microbiologist
 an infection preventionist
Institutional guidelines for the management of invasive Candida infections/
candidaemia
Additional interventions to improve the use of antifungals, including those
designed to detect and eliminate:
 Multidrug regimens with unnecessarily redundant antimicrobial spectra
 Antifungal therapy for the management of ‘fever’ syndromes (without
detection of fungi in sterile specimen) or cultures that represent
contamination or routine colonization
 Empiric regimens that are inadequately
 Regimens that do not adequately treat infections caused by
culture-conﬁrmed pathogens
Processes to measure and monitor antifungal use at the institutional level for
internal benchmarking
Periodic distribution of facility-speciﬁc epidemiological data together with the
rates of relevant in vitro susceptibilities to Candida pathogens
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enhanced in anaerobic media. The addition of special fungal
media may further enhance the speed and recovery of yeasts
from blood (‘Mycosis-IC/F-Medium’ or BacT/ALERT 3D).
Routine blood cultures are recommended after the initiation
of antifungal therapy, at the end of therapy, after therapy was
initiated (e.g. by day 3 to 5) or according to the current
ESCMID Candida guideline even daily until negativity [13,14]. In
addition, Candida guidelines recommend fundoscopy (and
transoesophageal echocardiography) to detect organ involve-
ment [13–15].
It is known for years that standard mycological diagnostics
using conventional blood culture systems may fail to diagnose
IC/C in up to 50% [16]. Noncultural tests (e.g. ß-D-Glucan,
Candida antigen and antibody tests, molecular tests) have been
advocated to close this diagnostic gap. Sensitivity (30–77%) and
speciﬁcity (70–88%) of Candida antibody (AB) tests vary widely
between different studies. Further improvements in the
sensitivity (76%) were achieved by the combination of the
Candida-speciﬁc antigens (e.g. Platelia-Candida, BioRad) with
the detection of Candida-speciﬁc antibodies (e.g. Platelia-
Candida) [17,18]. The detection of circulating 1,3-beta-D-
Glucan (BDG) from the cell wall of yeasts has been suggested
for the diagnosis of invasive candidosis. The test cannot
distinguish between infections due to different fungal agents
such as Candida, Aspergillus and Pneumocystis jirovecii [19–21]. In
a recent study from Italy in 377 patients, consecutively
admitted to ICU for sepsis, 95 patients having an ICU stay of
more than 5 days were studied [22]. The positive and negative
predictive values for a single-point BDG assay were higher
than those of Candida score and Candida colonization index.
However, long-term ICU patients were found to have elevated
BDG levels, not only due to invasive fungal infections, but also
due to the serious underlying diseases and conditions [21]. In a
study from the US, when BDG was compared with a Candida
PCR, PCR was found to be more sensitive than BDG for
diagnosing IC [23]. In contrast to this ‘conventional’ approach,
in prospective clinical study using real-time PCR (with
detection of six common Candida spp.) from serum samples
was found to correlate positively with blood culture results
but could give results within 1 day [24]. Candida PCR is now
regarded as the most promising tool for rapid diagnosis of IC/
C to close the ‘diagnostic gap’ [16,23].
What is the role of Candida scoring systems or colonization
index to detect IC/C?
Some strategies suggested the use of prediction rules or
speciﬁc scores (e.g. Candida scores, Candida colonization
index) to calculate the likelihood for acquiring invasive Candida
disease [25–27]. It has been shown that colonization must be
multifocal with detection of Candida spp from multiple samples
to be signiﬁcant. However, culturing Candida spp. from a
nonsterile site does not reﬂect disease but reﬂects more likely
colonization and should not prompt initiation of systemic
antifungal therapy. In fact, detection of Candida spp. in a single
nonsterile sample (e.g. broncho-alveolar lavage) does not
correlate with invasive disease and requires no systemic
treatment [28]. Even more difﬁcult, Candida scores may not be
able to distinguish between different Candida species. Whether
these scores and/or prediction rules are widely accepted and
applied in clinical practice is not known, but these models
could help, together with better diagnostic methods, to apply
antifungal drugs in a more directed way.
Which is the optimal antifungal drug treatment for
candidaemia, importance of non-Candida albicans species and
duration of therapy?
In all patients with documented IC/C, antifungal therapy
should be started within 24 h after a blood (or tissue from
sterile site) culture is positive for yeast [14,15]. The preferred
antifungal therapy for candidaemia and other systemic Candida
infections is either an echinocandin, such as anidulafungin
(200 mg ‘loading dose’, then 100 mg/day i.v.), caspofungin
(70 mg ‘loading dose’, then 50 mg/day iv.) or micafungin
(100 mg/day iv. without ‘loading dose’) and as alternative in
not critically ill patients without previous exposure to azoles
or infection by ﬂuconazole-resistant fungi ﬂuconazole (400–
800 mg/day iv.; with double dose as ‘loading dose’ on day 1)
(see Table 3) [29–33]. Fluconazole is generally effective for
C/IC, but is not regarded as the ﬁrst choice in critically ill
patients. Its use may be further hampered by an increasing
prevalence of infections due to Candida spp. with acquired or
intrinsic resistance to ﬂuconazole, such as C. glabrata and
C. krusei. Recent guidelines favour the echinocandin class of
antifungals as ﬁrst-line therapy in haemodynamically unstable
patients, in those with previous azole exposure and in clinical
settings with high local prevalence of ﬂuconazole-resistant
strains [14,15]. Empiric therapy with ﬂuconazole should not
be used in critically ill patients with sepsis or septic shock.
Instead, an echinocandin or liposomal amphotericin B should
be used in these patients. The use of D-AMB is associated
with signiﬁcant toxicity (infusion-related electrolyte imbal-
ances and nephrotoxicity). Its use is therefore discouraged
outside resource poor settings as a ﬁrst-line agent for the
treatment of IC. Candida albicans is still regarded as the most
prevalent Candida spp. (>60–70%) in BSI but the proportion
on non-Candida albicans spp. exceeds 50–60% in some
surveys [34]. In various reports from Europe (e.g. Denmark,
Spain), the proportion of Candida isolates nonsusceptible to
ﬂuconazole was increasing over the recent years [34,35].
Prior ﬂuconazole treatment has been described as an
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independent risk factor for candidaemia caused by microbi-
ologically conﬁrmed ﬂuconazole-resistant species in many but
not all studies [36,37]. In a seminational surveillance study
from Denmark, the proportion of Candida bloodstream
isolates with decreased susceptibility to ﬂuconazole exceeded
30% in 2006 [35]. However, this trend was not observed in
all European countries (e.g. in Switzerland no major changes
during a decade) [38]. Infection control and mycological
surveillance of Candida resistance with emergence of non-
Candida albicans spp. need to be monitored closely. In centres
with high prevalence of IC, infection control programmes are
needed (e.g. strict hand hygiene) to reduce nosocomial
infection rates. Most importantly, antifungal treatment for
uncomplicated candidaemia is recommended for 14 days after
the ﬁrst negative blood culture and together with resolution
of all clinical signs of infection.
How to balance between overuse (empirical therapy) and
underuse (waiting until proven disease) of antifungal therapy
in severely ill patients?
The high infection-related morbidity and mortality associated
with invasive Candida infection (IC), combined with suboptimal
diagnostic tools, have driven the overuse of antifungal drugs in
particular for empiric therapy of presumed IC. Antifungal
agents (e.g. ﬂuconazole) are widely used for prophylaxis and
empirical therapy of suspected invasive Candida infection in
ICU patients. Certain patient groups in the ICU may beneﬁt
from prophylactic use, but currently, the optimal target
population for antifungal prophylaxis remains unknown, as
this question has not been sufﬁciently addressed in clinical
trials [13,39,40]. Currently, only patients who had undergone
abdominal surgery and who had recurrent gastrointestinal
perforations or anastomotic leakages should be regarded as
candidates for ﬂuconazole prophylaxis but not the vast
majority of SICU patients [40]. According to a meta-analysis
on ﬂuconazole prophylaxis in surgical ICU patients (SICU),
prophylactic ﬂuconazole administration for prevention of
mycoses in SICU patients appears to successfully decrease
the rate of these infections, but this strategy does not
necessarily improve survival [41]. Because of the potential for
both resistance and emergence of non-Candida albicans
isolates, clinicians must consider these issues when evaluating
ﬂuconazole prophylaxis in the SICU.
In the ICU, empirical antifungal therapy against suspected
Candida infections (e.g. with guidance by positive biomarkers
such as ß-D-Glucan) is commonly applied in clinical practice
and supported by the IDSA Clinical Practice Guidelines for the
Management of Candidiasis [15]. The concept of AFS can be
directly applied to the prescription of empirical antifungal
therapy in the intensive care unit (ICU) because it is well-
known that inappropriate initial regimens lead to increased
mortality [42]. In a (historic) study from a hospital in the
TABLE 3. Recommendations for nongranulocytopenic adults with IC/C in three different guidelines: (i) joint recommendations
of the German Speaking Mycological Society (DMykG)/Paul-Ehrlich-Society for Chemotherapy (PEG), (ii) Infectious Disease
Society of America (IDSA) and (iiia) European Society for Clinical Microbiology and Infectious Diseases (ESCMID)
Antifungal drug Dosagea Evidence
Monotherapy DMykGb IDSAb ESCMID
Polyenesc
Amphotericin B deoxycholate (D-AMB) 0.7–1.0 mg/kg/day C-I A-I D-I
Liposomal amphotericin B (L-AMB) 3 mg/kg/day A-I A-I B-I
Amphotericin lipid complex (ABLC) 5 mg/kg/day C-II A-I C-II
Echinocandins
Anidulafungin Day 1, loading 200 mg/day
From day 2, 100 mg/day
A-I A-I A-I
Caspofungind Day 1, loading 70 mg/day
From day 2 1 9 50 mg/day
A-I A-I A-I
Micafungine 1 9 100 mg/day (without loading on day 1) A-I A-I A-I
Azoles
Fluconazole Day 1 loading (double dose)
From day 2 400–800 mg/day
A-I A-I C-I
Voriconazole Day 1, 2 9 6 mg/kg/day loading
From day 2, 2 9 3 mg/kg/day
A-I A-I B-I
Combination therapy
Amphotericin B deoxycholate + ﬂuconazole 0.7 mg/kg/day
800 mg/day
B-I B-III for endophthalmitis D-I
Amphotericin B deoxycholate + ﬂucytosine 0.7–1.0 mg/kg/day
4 9 25 mg/kg/day
C-III A-III for endophthalmitis;
generally recommended for
endocarditis, meningitis)
D-II
Lipid Amphotericin B + ﬂucytosine No data B-III (CNS) No data
aAll dosages are indicated for intravenous application.
bEvidence according to IDSA criteria [15].
cABCD is not listed here, because it is not licensed in many European countries.
dDose modiﬁcation in patients with more than 80 kg and with liver failure.
e(i) Dose modiﬁcations in patients <40 kg; (ii) optional dose increase to 200 mg/day i.v. or 4 mg/kg/day in patients ≤40 kg when insufﬁcient clinical response.
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United States in 1999, inappropriate initial antimicrobial/
antifungal therapy was observed in 86.6% of patients with
candidaemia [42]. Today, physicians taking care of immuno-
compromised patients tend to overuse antifungals. Doctors
are worried about a seriously ill patient with sepsis or shock
and tend to start empirical antifungal therapy when antibiotic
therapy failed. If antifungal therapy is not started within 24 h
after the diagnosis of Candida septic shock, overall fatality rate
is close to 100% [43]. In contrast, a study on empirical therapy
with ﬂuconazole in febrile ICU patients with FUO but without
shock did not show a beneﬁt over placebo for this treatment
approach [44]. Empirical antifungal therapy for suspected
invasive Candida infection in the ICU may lead to overuse of
antifungal drugs and should not be regarded as standard of care
unless the use of additional diagnostic tools (e.g. biomarkers)
indicate invasive disease [45].
When to apply step-down/de-escalation strategies?
De-escalation strategies (switch from i.v. echinocandin therapy
after initial response to oral therapy with an azole antifungal
drug) are commonly used. However, criteria for ‘early switch’
(e.g. after 3–5 days) are not clearly established in contrast to
‘late switch’ after 10 days of effective therapy as recom-
mended in current guidelines [13,14]. After improvement in
clinical signs, sterilization of blood cultures and documented in
vitro susceptibility of the causative yeast, step-down therapy
after initial treatment with an echinocandin (anidulafungin,
caspofungin and micafungin) was shown to be effective with
oral ﬂuconazole (or voriconazole) starting on day 10 of
antifungal therapy and may be recommended if oral drug intake
and gastrointestinal absorption are possible. [31,32,46,47]
Importantly, further criteria may apply, such as identiﬁcation of
a susceptible organism in a clinically stable patient with
negative blood culture results.
How important is the catheter removal in IC/C?
Central venous lines should be regarded as an infectious focus
of candidaemia and should be removed whenever possible,
regardless if they are the primary portal of entry or if they are
secondarily colonized [15,48]. A rapid sterilization of the
bloodstream is only achieved by the removal of infected
central venous lines including implanted catheters (e.g. Port-/
Hickman-/Broviac-Systems). Removal should be carried out
together with the initiation of antifungal therapy. If the central
venous lines are retained, the duration of candidaemia
increases (from 3 to 6 days) as does the mortality of patients
[48–51]. This is particularly supported by data for infections
due to C. albicans and C. parapsilosis, but less for other Candida
species. The best time for removal is controversial but should
generally be carried out as early as possible.
How to achieve the most cost-effective antifungal therapy
(pharmacoeconomics)?
In general, treatment of patients with invasive fungal infections
may be associated with signiﬁcantly higher inpatient hospital
cost compared with controls [52]. In a large propensity
analysis in an estimated 1118 hospital admissions of paediatric
patients and 8949 hospital admissions of adult patients from
the United States in 2000, in adult patients, candidaemia was
associated with an increase in mortality, increase in length of
stay and a mean increase in hospital charges [53]. According to
a case–control study from the United States, candidaemia itself
did not increase the total hospital charges and cost of
hospitalization; having received adequate treatment for candi-
daemia, but signiﬁcantly increased the total hospital charges
and cost of hospitalization [54,55]. Toxicity of the ‘old’
antifungals (e.g. amphotericin B deoxycholate) was of major
concern in the past, but there were no many choices. Newer
antifungal agents (e.g. liposomal amphotericin B, echinocan-
dins) are not only safer, but have equal or even better efﬁcacy
and are easier to administer [9]. Unfortunately, most of these
newer antifungal drugs are more expensive, and physicians are
confronted to regulations by hospital administrators and
pharmacists to reduce or even avoid their use in clinical
practice during hospital stay for ﬁnancial reasons (at least in
Europe common practice). Certainly, this may differ from
institution to institution. Not only due to cost issues but to
decrease high rate of multidrug-resistant pathogens (MDRP) in
the hospital, formulary restrictions and pre-authorization
strategies are discussed in the literature on AMS/AFS [11,56].
Several recent pharmacoeconomic studies have indicated
that ‘newer’ antifungal agents (e.g. echinocandins) are associ-
ated with higher directly drug-related pharmacy costs. Most
studies examined different parameters and are therefore
difﬁcult to compare. In a recent analysis, micafungin (MICA)
was regarded as a more cost-effective therapy in the
treatment of IC/C when compared with L-AMB, primarily
because of less nephrotoxicity using MICA and less direct drug
costs [57]. A direct economic comparison between echino-
candins found MICA to be cost equivalent to caspofungin in
treating IC/C, with variation in drug acquisition cost the
critical factor [58].
In an economic analysis of ﬂuconazole vs. anidulafungin
(AND), Neoh et al. found AND to be cost-effective despite
higher directly drug-related cost with AND [59]. This model
calculated the lower overall mortality rates in favour of AND
in patients treated with for IC/C, which lead to this conclusion.
It may be concluded that no substantial increase in the total
cost for the patient care treated for IC/C is observed with
‘newer’ antifungal agents because other ‘indirect’ costs may be
reduced (e.g. treatment of adverse events, reduced length of
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hospital stay, mortality) and economic differences in use of
antifungal drugs may be inﬂuenced by several factors
[52,57,59,60]. The higher drug-related costs have to be
balanced with the clinical beneﬁt and patient outcome.
Implementation of an AFS for IC/C in the
Hospital
Implementation of an AFS programme for IC/C requires a
multidisciplinary approach, and it was suggested that an
infectious diseases physician and a clinical pharmacist with
infectious diseases training are its core team members [61]. In
addition, a clinical microbiologist and infection control expert
need to be involved in order to address the emergence of
MDRP and infection control issues adequately [62] (see
Table 2).
The implementation of national or international guidelines
written from experts in the ﬁeld is a ﬁrst step to adapt
recommendations from guidelines into local everyday practice
[13–15,63]. Recently, in the United Kingdom, the compliance
and implementation of the British Society for Medical Mycol-
ogy standards of care for patients with invasive infections in
UK hospitals were audited. Apparently, recommendations
which are believed to be essential for adequate patient care,
such as early removal of the central venous catheter (CVC),
were followed in the majority of patients [64]. In patients
presenting with candidaemia, CVCs were changed routinely
within 48 h in 85%. It has been shown that compliance with a
speciﬁc AFS programme depends on ID specialist consultation
(e.g. routine ophthalmological examinations to exclude sys-
temic IC) [65]. Thus, guidance appears to be helpful, but there
is substantial room for improvement, in particular how to use
and apply diagnostic tests, antifungal agents and restriction
policies.
In summary, AFS programmes should be organized by an
interdisciplinary team of clinicians, pharmacists, microbiolo-
gists and infection control experts with the lead of an
infectious disease specialist preferably in each large hospital/
institution dealing with high-risk patients for invasive fungal
infections. These programmes should consider various aspects
of IC/C including as follows: (i) the local fungal epidemiology,
(ii) information on antifungal resistance rates, (iii) establishing
and application of therapeutic guidelines, (iv) implementation
of treatment strategies for empirical, pre-emptive therapy
including PK/PD data for antifungal drugs, de-escalation and
‘switch and step-down strategies’ (from intravenous to oral
medication) in deﬁned patient populations, (v) catheter
management together with the application of routine diagnos-
tic procedures such as ophthalmological and cardiac evalua-
tions, and (vi) the best available diagnostic tests for diagnosing
IC and candidaemia.
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